Rezultati pretraživanja
  1. prije 6 sati
  2. prije 8 sati
  3. prije 9 sati

    My winning trades today were . I only had one losing trade today in .

  4. 🔴 You are invited to test drive Trade-Ideas Premium' features for 10 days! Feb 03 to 14th via ⟶ 📊

  5. prije 12 sati

    Plutus Longus Practicus 2020-02-03 12:40 EST. *Closed/Sold Existing: at $100.93 for 2.09 profit (2.11%). Alexion Pharmaceuticals, Inc (CORP). Trade Id: 34180680803010576. (P&L not vailable due to system upgrades) Stats:

  6. prije 14 sati

    P3s include 1st cohort of pts Rxd for both Wet AMD & Geographic Atrophy (Dry AMD) in Same trial-addressing real life Retinal concerns as both Lucentis & Eyelea showed 33% of pts had GA w/ 2yrs of treatment. showed nearly 2x effect in GA - had none.

  7. prije 15 sati

    . Such a no brainer… STONG BUY!

  8. prije 16 sati
  9. 2. velj

    Alexion Pharmaceuticals Updates FY20 Earnings Guidance

  10. 2. velj

    Short sale volume(not short interest) for on 2020-01-31 is 77%. 42% 40% 38% 31%

  11. 2. velj

    has reported a press announcing its past performance on 30th Jan, 2020. High accruals in reported profits, low future profitability, see:

  12. 1. velj

    Two days ago, shown an announcement of earnings in 2019. When earnings quality is low, high reported earnings may relate to low future earnings, see:

  13. 31. sij
  14. 2020 guidance for total revenue is $5.5-$5.56B, which is lighter than current consensus of $5.7B. Revenue guidance for Soliris/Ultomiris looks in-line, so the shortfall could be metabolic revenue.

  15. 29. sij
  16. 29. sij
  17. 28. sij

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.